At the last World Orphan Drug congress asia in 2013, Fuminori Yoshida of SymBio gave the following presentation entitled:
Effort to establish an infrastructure for orphan drug development in Asia Pacific – SymBio’s Blue Ocean Strategy.
Some of the points he covered in this presentation include:
- Creating an ecosystem which encourages orphan drug development
- Patient centered development process
- Blue ocean strategy
- Potential use of Rigosertib and TREAKISYM as orphan drugs
If you find this presentation informative and interesting, you may wish to join us at the upcoming World Orphan drug congress Asia happening in June. Visit our website for more information.